ORAMED PHARMACEUTICALS INC. Available-for-sale Securities, Gross Unrealized Loss
ORAMED PHARMACEUTICALS INC. (ORMP) reported Available-for-sale Securities, Gross Unrealized Loss of -$4.00 thousand for the 3-month period ending 2016-11-30, per its 10-Q filed 2017-01-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2017-01-11
- ORAMED PHARMACEUTICALS INC. available-for-sale securities, gross unrealized loss for the quarter ending 2016-11-30 was -$4.00K.
- ORAMED PHARMACEUTICALS INC. available-for-sale securities, gross unrealized loss for fiscal 2015 was $4.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|
| 2016-11-30 | -$4.00K 10-Q · filed 2017-01-11 | |
| 2015-08-31 | $4.00K 10-K · filed 2015-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |